342 related articles for article (PubMed ID: 19466411)
1. Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent.
Chun AW; Cosenza SC; Taft DR; Maniar M
Cancer Chemother Pharmacol; 2009 Dec; 65(1):177-86. PubMed ID: 19466411
[TBL] [Abstract][Full Text] [Related]
2. Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs.
Kobayashi S; Sakai T; Dalrymple PD; Wood SG; Chasseaud LF
Arzneimittelforschung; 1993 Dec; 43(12):1367-77. PubMed ID: 8141830
[TBL] [Abstract][Full Text] [Related]
3. Preclinical pharmacology of 2-methoxyantimycin A compounds as novel antitumor agents.
Wang H; Li M; Rhie JK; Hockenbery DM; Covey JM; Zhang R; Hill DL
Cancer Chemother Pharmacol; 2005 Sep; 56(3):291-8. PubMed ID: 15883820
[TBL] [Abstract][Full Text] [Related]
4. Species differences in troxacitabine pharmacokinetics and pharmacodynamics: implications for clinical development.
Gourdeau H; Leblond L; Hamelin B; Dong K; Ouellet F; Boudreau C; Custeau D; Richard A; Gilbert MJ; Jolivet J
Clin Cancer Res; 2004 Nov; 10(22):7692-702. PubMed ID: 15570003
[TBL] [Abstract][Full Text] [Related]
5. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
Marathe PH; Kamath AV; Zhang Y; D'Arienzo C; Bhide R; Fargnoli J
Cancer Chemother Pharmacol; 2009 Dec; 65(1):55-66. PubMed ID: 19396600
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic characterization of a natural product-inspired novel MEK1 inhibitor E6201 in preclinical species.
Kumar V; Schuck EL; Pelletier RD; Farah N; Condon KB; Ye M; Rowbottom C; King BM; Zhang ZY; Saxton PL; Wong YN
Cancer Chemother Pharmacol; 2012 Jan; 69(1):229-37. PubMed ID: 21698359
[TBL] [Abstract][Full Text] [Related]
7. Effects of formulation and route of administration on the systemic availability of Ex-RAD®, a new radioprotectant, in preclinical species.
Chun AW; Freshwater RE; Taft DR; Gillum AM; Maniar M
Biopharm Drug Dispos; 2011 Mar; 32(2):99-111. PubMed ID: 21341279
[TBL] [Abstract][Full Text] [Related]
8. Preclinical pharmacokinetic analysis of felotaxel (SHR110008), a novel derivative of docetaxel, in rats and its protein binding ability in vitro.
Ding Y; Liu W; Lu C; Yang J; Zhu Y; Song Y; Ma Z; Yang L; Jia Y; Wen A
Biomed Pharmacother; 2012 Mar; 66(2):98-102. PubMed ID: 22264880
[TBL] [Abstract][Full Text] [Related]
9. Preclinical pharmacology of the novel antitumor agent adaphostin, a tyrphostin analog that inhibits bcr/abl.
Li M; Wang H; Hill DL; Stinson S; Veley K; Grossi I; Peggins J; Covey JM; Zhang R
Cancer Chemother Pharmacol; 2006 May; 57(5):607-14. PubMed ID: 16331493
[TBL] [Abstract][Full Text] [Related]
10. Preclinical pharmacology of epothilone D, a novel tubulin-stabilizing antitumor agent.
Wang H; Wang Z; Wang S; Li M; Nan L; Rhie JK; Covey JM; Zhang R; Hill DL
Cancer Chemother Pharmacol; 2005 Sep; 56(3):255-60. PubMed ID: 15868148
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the cassette dosing approach for assessing the pharmacokinetics of geldanamycin analogues in mice.
Smith NF; Hayes A; Nutley BP; Raynaud FI; Workman P
Cancer Chemother Pharmacol; 2004 Dec; 54(6):475-86. PubMed ID: 15526201
[TBL] [Abstract][Full Text] [Related]
12. The pharmacokinetic behavior of the photosensitizer meso-tetra-hydroxyphenyl-chlorin in mice and men.
Triesscheijn M; Ruevekamp M; Out R; Van Berkel TJ; Schellens J; Baas P; Stewart FA
Cancer Chemother Pharmacol; 2007 Jun; 60(1):113-22. PubMed ID: 17009028
[TBL] [Abstract][Full Text] [Related]
13. Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions.
Choo EF; Belvin M; Boggs J; Deng Y; Hoeflich KP; Ly J; Merchant M; Orr C; Plise E; Robarge K; Martini JF; Kassees R; Aoyama RG; Ramaiya A; Johnston SH
Drug Metab Dispos; 2012 May; 40(5):919-27. PubMed ID: 22315332
[TBL] [Abstract][Full Text] [Related]
14. Preclinical pharmacology of the natural marine product dolastatin 10 (NSC 376128).
Newman RA; Fuentes A; Covey JM; Benvenuto JA
Drug Metab Dispos; 1994; 22(3):428-32. PubMed ID: 8070319
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of muraglitazar (BMS-298585), a dual peroxisome proliferator-activated receptors (PPAR) alpha and gamma activator, in mice, rats, dogs, and monkeys.
Hosagrahara VP; Chandrasena G; Chang SY; Koplowitz B; Hariharan N; Cheng PT; Humphreys WG
Xenobiotica; 2006 Dec; 36(12):1227-38. PubMed ID: 17162469
[TBL] [Abstract][Full Text] [Related]
16. Disposition of abouthiouzine: a novel antihyperthyroid drug.
Alkharfy KM; Khan RM; Al-Hadiya BM; Abou-Auda HS; Abou-Shaaban RR
Biopharm Drug Dispos; 2007 Apr; 28(3):105-11. PubMed ID: 17230598
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia.
Fan Q; Leuther KK; Holmes CP; Fong KL; Zhang J; Velkovska S; Chen MJ; Mortensen RB; Leu K; Green JM; Schatz PJ; Woodburn KW
Exp Hematol; 2006 Oct; 34(10):1303-11. PubMed ID: 16982323
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic studies in mice of two new thioxanthenones (183577 and 232759) that showed preferential solid tumor activity.
Foster BJ; Wiegand RA; Pugh S; LoRusso PM; Rake J; Corbett TH
Clin Cancer Res; 1997 Nov; 3(11):2047-53. PubMed ID: 9815596
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, pharmacodynamics and metabolism of a novel anticancer agent for prostate cancer.
Yang J; Ahn S; Wu Z; Hwang DJ; Miller DD; Dalton JT
Int J Oncol; 2012 Jul; 41(1):337-44. PubMed ID: 22576690
[TBL] [Abstract][Full Text] [Related]
20. Murine toxicology and pharmacokinetics of novel retinoic acid metabolism blocking agents.
Patel JB; Khandelwal A; Chopra P; Handratta VD; Njar VC
Cancer Chemother Pharmacol; 2007 Nov; 60(6):899-905. PubMed ID: 17345084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
